Filing Flows › Siga Technologies (SIGA) › Guidance & outlook
Siga Technologies (SIGA) guidance and outlook
Siga Technologies' 10-Q filed Nov 9, 2026 makes 6 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 9, 2026
- Based on recent feedback from the FDA, which requested that the Company perform additional validation and related laboratory work to help ensure the accuracy of results from the CDC's sample analysis, the Company expects its submission of a Supplemental NDA will occur in 2028.
- Unexercised options specify potential payments up to approximately $5.6 million in total (if all such options are exercised), all of which relates to supportive activities that we currently do not expect to be required.
- The Company estimates that sales of the IV formulation under this contract (under current terms), would have a gross margin (sales less cost of sales, as a percentage of sales) that is less than 40%.
- Under the terms of the agreement, the Company will be the sole manufacturer of tecovirimat and will supply finished product to Hikma.
- Our effective tax rates for the periods ended September 30, 2026 and 2025 differ from the statutory rate primarily as a result of currently forecasted losses for the full year, state taxes and non-deductible executive compensation under Internal Revenue Code Section 162(m).
- In connection with the Retirement and Consulting Agreement discussed in Note 15 Subsequent Event , the Company expects to make cash payments, including those in connection with consulting services, totaling approximately $1.9 million over the next two years.
Siga Technologies' latest quarter
Siga Technologies, Q3 2026: revenue $1.3M (-50% year over year), operating margin -495.1%, net loss $2.9M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
Questions
What does Siga Technologies expect?
Based on recent feedback from the FDA, which requested that the Company perform additional validation and related laboratory work to help ensure the accuracy of results from the CDC's sample analysis, the Company expects its submission of a Supplemental NDA will occur in 2028. Unexercised options specify potential payments up to approximately $5.6 million in total (if all such options are exercised), all of which relates to supportive activities that we currently do not expect to be required. The Company estimates that sales of the IV formulation under this contract (under current terms), woul
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.